Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Loures – page 47

658 clinical trials in Loures, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Loures at a glance
658
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

658 trials in Loures

Open in trial search

Study on Ofatumumab for Patients with Relapsing Multiple Sclerosis Transitioning from Fumarate-Based Therapies or Fingolimod

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on MK-2060 for Preventing Blood Clots in Dialysis Patients with End-Stage Kidney Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:MK-2060
  • Sponsor:Merck Sharp & Dohme LLC

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca AB

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Celgene Corp.

Lupus nephritis

Not recruiting

Study on the Effectiveness and Safety of Iptacopan with Drug Combination for Adults with Active Lupus Nephritis Class III-IV, +/- V

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Short stature+3

Not recruiting

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Loures

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, particularly exploring new therapies for HER2-positive and hormone receptor-positive variants. Studies include novel combinations of targeted therapies and immunotherapy approaches.

  • Advanced breast cancer therapies
  • HER2-positive treatment strategies
  • Non-small cell lung cancer interventions

Research includes evaluation of drugs like trastuzumab deruxtecan and combination therapies targeting specific cancer mutations.

02 Neurological Disorders

Comprehensive studies investigating treatments for multiple sclerosis and neurodegenerative conditions. Research focuses on both relapsing and progressive forms of MS, along with early-stage Alzheimer's disease.

  • Multiple sclerosis therapies
  • Alzheimer's disease treatments
  • Cognitive function studies

Trials evaluate medications like ocrelizumab and semaglutide for various neurological conditions.

03 Inflammatory Conditions

Advanced research into inflammatory bowel diseases, including studies on Crohn's Disease and Ulcerative Colitis. Trials evaluate novel therapeutic approaches and combination treatments.

  • Crohn's Disease management
  • Ulcerative Colitis treatments
  • Combination therapy approaches

Studies investigate medications such as risankizumab and ozanimod for long-term disease management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.